Serveur d'exploration Tocilizumab

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Languedoc-Roussillon71
T. Schaeverbeke9
Languedoc-Roussillon Sauf T. Schaeverbeke" 64
T. Schaeverbeke Sauf Languedoc-Roussillon" 2
Languedoc-Roussillon Et T. Schaeverbeke 7
Languedoc-Roussillon Ou T. Schaeverbeke 73
Corpus6869
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 7.
Ident.Authors (with country if any)Title
002A05 A. Frazier-Mironer [France] ; A. Cantagrel [France] ; B. Combe [France] ; V. Deschamps ; M. Dougados [France] ; R.-M. Flipo ; I. Logeart ; X. Mariette ; T. Schaeverbeke ; J. Sibilia [France] ; X. Le Loët [France]THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study
002A30 S. Godot [France] ; J. E. Gottenberg [France] ; S. Paternotte ; I. Pane [France] ; B. Combe [France] ; J. Sibilia [France] ; R.-M. Flipo ; T. Schaeverbeke ; P. Ravaud [France] ; E. Toussirot ; F. Berenbaum [France] ; X. Mariette [France] ; D. Wendling ; J. Sellam [France]THU0122 Safety of surgery in patients with rheumatoid arthritis treated by rituximab in routine care: Data from the french air registry
002E03 J. H. Salmon ; P. Ravaud [France] ; T. Bardin ; P. Cacoub [France] ; A. Cantagruel [France] ; B. Combe [France] ; M. Dougados [France] ; R.-M. Flipo ; B. Godeau ; L. Guillevin [France] ; X. Le Loët ; E. Hachulla ; T. Schaeverbeke ; J. Sibilia [France] ; I. Pane [France] ; G. Baron ; X. Mariette [France] ; J.-E. Gottenberg [France]FRI0246 Serious infusion-related reactions after rituximab in patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry
002E04 J. Morel [France] ; M. O. Duzanski [France] ; A. Cantagrel [France] ; B. Combe [France] ; M. Dougados [France] ; R. M. Flipo ; J. E. Gottenberg [France] ; X. Mariette [France] ; O. Vittecoq ; A. Saraux ; T. Schaeverbeke ; T. Bardin [France] ; M. Soubrier ; P. Ravaud [France] ; J. Siblia [France]FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra)
002E50 M. Kostine ; T. Barnetche ; E. Ardouin ; M. Joly [France] ; E. Rabois [France] ; B. Glace [France] ; T. Schaeverbeke ; C. RichezFRI0192 Is early neutropenia associated with clinical response in patients receiving tocilizumab in rheumatoid arthritis?
003142 B. Combe [France] ; M. Dougados [France] ; I. Logeart ; C. Lukas [France] ; X. Mariette [France] ; X. Puechal ; A. Saraux ; T. Schaeverbeke [France]AB0516 An open-label randomized controlled study to evaluate the efficacy of etanercept (ETN) versus rituximab (RTX), in patients with active rheumatoid arthritis previously treated with RTX and TNF blockers
003560 J E Gottenberg [France] ; P. Ravaud [France] ; A. Cantagrel [France] ; B. Combe [France] ; R M Flipo [France] ; T. Schaeverbeke [France] ; E. Houvenagel [France] ; P. Gaudin [France] ; D. Loeuille [France] ; S. Rist [France] ; M. Dougados [France] ; J. Sibilia [France] ; X. Le Loët [France] ; C. Marcelli [France] ; T. Bardin [France] ; I. Pane [France] ; G. Baron [France] ; X. Mariette [France]Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021